DK2439284T3 - Fremgangsmåde til at bestemme reaktivitet af cancer på behandlinger målrettet mod epidermal vækstfaktor-receptor - Google Patents

Fremgangsmåde til at bestemme reaktivitet af cancer på behandlinger målrettet mod epidermal vækstfaktor-receptor Download PDF

Info

Publication number
DK2439284T3
DK2439284T3 DK11178194.4T DK11178194T DK2439284T3 DK 2439284 T3 DK2439284 T3 DK 2439284T3 DK 11178194 T DK11178194 T DK 11178194T DK 2439284 T3 DK2439284 T3 DK 2439284T3
Authority
DK
Denmark
Prior art keywords
reactivity
cancer
procedure
determining
growth factor
Prior art date
Application number
DK11178194.4T
Other languages
English (en)
Inventor
Daphne Winifred Bell
Daniel A Haber
Pasi Antero Janne
Bruce E Johnson
Matthew Meyerson
Juan Guillermo Paez
William R Sellers
Raffaella Sordella
Thomas J Lynch
Jeffrey E Settleman
Original Assignee
Massachusetts Gen Hospital
Dana Farber Cancer Inst Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35064318&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2439284(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Massachusetts Gen Hospital, Dana Farber Cancer Inst Inc filed Critical Massachusetts Gen Hospital
Application granted granted Critical
Publication of DK2439284T3 publication Critical patent/DK2439284T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/485—Epidermal growth factor [EGF] (urogastrone)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
DK11178194.4T 2004-03-31 2005-03-31 Fremgangsmåde til at bestemme reaktivitet af cancer på behandlinger målrettet mod epidermal vækstfaktor-receptor DK2439284T3 (da)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US55821804P 2004-03-31 2004-03-31
US56109504P 2004-04-09 2004-04-09
US56575304P 2004-04-27 2004-04-27
US56598504P 2004-04-27 2004-04-27
US57403504P 2004-05-25 2004-05-25
US57791604P 2004-06-07 2004-06-07
US59228704P 2004-07-29 2004-07-29
EP05757467.5A EP1733056B1 (en) 2004-03-31 2005-03-31 Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments

Publications (1)

Publication Number Publication Date
DK2439284T3 true DK2439284T3 (da) 2019-07-29

Family

ID=35064318

Family Applications (5)

Application Number Title Priority Date Filing Date
DK05757467.5T DK1733056T3 (da) 2004-03-31 2005-03-31 Fremgangsmåde til bestemmelse af responsiviteten af en tumor på behandlinger med den epidermale vækstfaktor-receptor som mål
DK11178198.5T DK2447375T3 (da) 2004-03-31 2005-03-31 Fremgangsmåde til bestemmelse af responsiviteten af en tumor på behandlinger med den epidermale vækstfaktor-receptor som mål
DK11178200.9T DK2423331T3 (da) 2004-03-31 2005-03-31 Fremgangsmåde til at bestemme reaktivitet af cancer på behandlinger målrettet mod epidermal vækstfaktor-receptor
DK11178202.5T DK2439285T3 (da) 2004-03-31 2005-03-31 Fremgangsmåde til at bestemme reaktivitet af cancer på behandlinger målrettet mod epidermal vækstfaktor-receptor
DK11178194.4T DK2439284T3 (da) 2004-03-31 2005-03-31 Fremgangsmåde til at bestemme reaktivitet af cancer på behandlinger målrettet mod epidermal vækstfaktor-receptor

Family Applications Before (4)

Application Number Title Priority Date Filing Date
DK05757467.5T DK1733056T3 (da) 2004-03-31 2005-03-31 Fremgangsmåde til bestemmelse af responsiviteten af en tumor på behandlinger med den epidermale vækstfaktor-receptor som mål
DK11178198.5T DK2447375T3 (da) 2004-03-31 2005-03-31 Fremgangsmåde til bestemmelse af responsiviteten af en tumor på behandlinger med den epidermale vækstfaktor-receptor som mål
DK11178200.9T DK2423331T3 (da) 2004-03-31 2005-03-31 Fremgangsmåde til at bestemme reaktivitet af cancer på behandlinger målrettet mod epidermal vækstfaktor-receptor
DK11178202.5T DK2439285T3 (da) 2004-03-31 2005-03-31 Fremgangsmåde til at bestemme reaktivitet af cancer på behandlinger målrettet mod epidermal vækstfaktor-receptor

Country Status (14)

Country Link
US (8) US7294468B2 (da)
EP (6) EP2439285B1 (da)
JP (6) JP4350148B2 (da)
KR (3) KR101347613B1 (da)
CN (6) CN107988363A (da)
AU (4) AU2005228446B2 (da)
BR (1) BRPI0508286B8 (da)
CA (1) CA2556227C (da)
DK (5) DK1733056T3 (da)
ES (5) ES2425749T3 (da)
HK (4) HK1208250A1 (da)
PT (1) PT1733056E (da)
SI (1) SI1733056T1 (da)
WO (1) WO2005094357A2 (da)

Families Citing this family (173)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7219016B2 (en) 2001-04-20 2007-05-15 Yale University Systems and methods for automated analysis of cells and tissues
EP1392359B2 (en) 2001-05-11 2013-03-13 Ludwig Institute for Cancer Research Ltd. Specific binding proteins and uses thereof
US20100056762A1 (en) 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
AU2005228446B2 (en) 2004-03-31 2007-02-22 Dana-Farber Cancer Institute, Inc. Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments
ES2564127T5 (es) 2004-06-04 2020-03-26 Genentech Inc Mutaciones en EGFR
TW200617396A (en) * 2004-10-06 2006-06-01 Astrazeneca Ab Method
ES2359322T3 (es) * 2004-10-18 2011-05-20 Brandeis University Procedimiento para la amplificación de ácidos nucleicos.
WO2006070667A1 (ja) * 2004-12-28 2006-07-06 Takara Bio Inc. Ｅｇｆｒ遺伝子変異の検出法ならびに検出キット
CN102886045A (zh) 2005-02-03 2013-01-23 综合医院公司 治疗吉非替尼耐药性癌症的方法
CA2597673C (en) 2005-02-11 2014-07-08 Harold Varmus Methods and compositions for detecting a drug resistant egfr mutant
KR20070106029A (ko) * 2005-02-24 2007-10-31 암젠 인코포레이티드 상피세포 성장 인자 수용체 돌연변이
GB0506670D0 (en) * 2005-04-01 2005-05-11 Astrazeneca Ab Method
GB2424886A (en) * 2005-04-04 2006-10-11 Dxs Ltd Polynucleotide primers against epidermal growth factor receptor and method of detecting gene mutations
EP1874920A4 (en) 2005-04-05 2009-11-04 Cellpoint Diagnostics DEVICES AND METHODS FOR ENRICHING AND MODIFYING CIRCULATING TUMOR CELLS AND OTHER PARTICLES
WO2006113151A2 (en) * 2005-04-14 2006-10-26 Wyeth Use of an epidermal growth factor receptor kinase inhibitor (egfr) in gefitinib resistant patients
EP1913157B2 (en) * 2005-06-28 2016-10-26 Genentech, Inc. Egfr and kras mutations for prediction of patient response to egfr inhibitor treatment
KR20080028857A (ko) * 2005-10-05 2008-04-01 아스트라제네카 유케이 리미티드 ＥｒｂＢ 수용체 약물에 대한 환자반응을 예측 및 모니터링하는 방법
CA2626326C (en) 2005-11-04 2021-02-16 Wyeth Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272
EP1948180B1 (en) * 2005-11-11 2013-03-13 Boehringer Ingelheim International GmbH Combination treatment of cancer comprising egfr/her2 inhibitors
CA2833706C (en) 2005-11-11 2014-10-21 Boehringer Ingelheim International Gmbh Quinazoline derivatives for the treatment of cancer diseases
JPWO2007099852A1 (ja) * 2006-02-23 2009-07-16 国立大学法人金沢大学 固形癌のチロシンキナーゼ阻害剤に対する感受性を検査する方法及び検査キット
US7867775B2 (en) * 2006-03-31 2011-01-11 Biodesix, Inc. Selection of head and neck cancer patients for treatment with drugs targeting EGFR pathway
US7736905B2 (en) * 2006-03-31 2010-06-15 Biodesix, Inc. Method and system for determining whether a drug will be effective on a patient with a disease
US7906342B2 (en) 2006-03-31 2011-03-15 Biodesix, Inc. Monitoring treatment of cancer patients with drugs targeting EGFR pathway using mass spectrometry of patient samples
CA2650776A1 (en) 2006-05-05 2007-11-15 Yale University Immunohistochemical methods for determining signal transduction activity in tumors
US8768629B2 (en) * 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
JP2009537154A (ja) * 2006-05-18 2009-10-29 モレキュラー プロファイリング インスティテュート， インコーポレイテッド 疾患状態に対する個別化された医学的介入を決定するためのシステムおよび方法
EP3424598B1 (en) 2006-06-14 2022-06-08 Verinata Health, Inc. Rare cell analysis using sample splitting and dna tags
EP2589668A1 (en) 2006-06-14 2013-05-08 Verinata Health, Inc Rare cell analysis using sample splitting and DNA tags
US7709222B2 (en) * 2006-07-13 2010-05-04 Yale University Methods for making cancer prognoses based on subcellular localization of biomarkers
BRPI0717586A2 (pt) * 2006-09-18 2013-10-29 Boehringer Ingelheim Int Método para tratar câncer apresentando mutações do egfr
WO2008038812A1 (fr) * 2006-09-28 2008-04-03 Shimadzu Corporation Procédé permettant de préparer un échantillon pour la spectrométrie de masse à désorption-ionisation laser assistée par matrice et procédé de spectrométrie de masse à désorption-ionisation laser assistée par matrice
JP4795203B2 (ja) * 2006-11-13 2011-10-19 シスメックス株式会社 アンスラサイクリン系抗癌剤の感受性判定方法及びそのシステム
ES2609094T3 (es) 2007-01-25 2017-04-18 Dana-Farber Cancer Institute, Inc. Uso de anticuerpos anti-EGFR en el tratamiento de enfermedades mediadas por un EGFR mutante
PT2129396E (pt) * 2007-02-16 2013-11-18 Merrimack Pharmaceuticals Inc Anticorpos contra erbb3 e suas utilizações
WO2008112269A2 (en) 2007-03-13 2008-09-18 Amgen Inc. K-ras mutations and anti-egfr antibody therapy
PL2412828T3 (pl) * 2007-03-13 2013-11-29 Amgen Inc Mutacje K-ras i B-raf i terapia przeciwciałami anty-EGFr
CA2680854C (en) 2007-03-15 2017-02-14 Ludwig Institute For Cancer Research Treatment method using egfr antibodies and src inhibitors and related formulations
US8642067B2 (en) 2007-04-02 2014-02-04 Allergen, Inc. Methods and compositions for intraocular administration to treat ocular conditions
US8999634B2 (en) 2007-04-27 2015-04-07 Quest Diagnostics Investments Incorporated Nucleic acid detection combining amplification with fragmentation
KR20100024410A (ko) * 2007-05-11 2010-03-05 엔즌 파마슈티칼스, 인코포레이티드 Ｈｅｒ３ 조절용 ｒｎａ 길항제 화합물
WO2009005715A1 (en) * 2007-06-29 2009-01-08 Yale University Methods for a predictive diagnostic test for tamoxifen
MX2010001757A (es) 2007-08-14 2010-09-14 Ludwig Inst Cancer Res Anticuerpo monoclonal 175 que activa el receptor egf y derivados y usos del mismo.
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
EP3190192A1 (en) 2008-02-01 2017-07-12 The General Hospital Corporation Use of microvesicles in diagnosis and prognosis of medical diseases and conditions
CN102066573A (zh) * 2008-04-03 2011-05-18 哈森阿尔法生物技术研究院 用于扩增多个靶标的扩增子拯救多重聚合酶链式反应
US8137919B2 (en) * 2008-04-10 2012-03-20 Montefiore Medical Center Method of determining the sensitivity of cancer cells to EGFR inhibitors including cetuximab, panitumumab and erlotinib
CN101445829B (zh) * 2008-04-23 2013-06-05 广州益善生物技术有限公司 Egfr基因突变位点的检测探针、液相芯片及其检测方法
KR20130088908A (ko) 2008-06-17 2013-08-08 와이어쓰 엘엘씨 Ｈｋｉ-272 및 비노렐빈을 함유하는 항신생물성 조합물
EP3175853B1 (en) 2008-08-04 2023-11-01 Wyeth LLC Antineoplastic combinations of neratinib and capecitabine
NZ591137A (en) * 2008-08-15 2012-10-26 Merrimack Pharmaceuticals Inc Methods and systems for predicting response of cells to a therapeutic agent
GB2467691A (en) 2008-09-05 2010-08-11 Aueon Inc Methods for stratifying and annotating cancer drug treatment options
US9156010B2 (en) 2008-09-23 2015-10-13 Bio-Rad Laboratories, Inc. Droplet-based assay system
US8709762B2 (en) 2010-03-02 2014-04-29 Bio-Rad Laboratories, Inc. System for hot-start amplification via a multiple emulsion
US9132394B2 (en) 2008-09-23 2015-09-15 Bio-Rad Laboratories, Inc. System for detection of spaced droplets
US9399215B2 (en) 2012-04-13 2016-07-26 Bio-Rad Laboratories, Inc. Sample holder with a well having a wicking promoter
WO2011120024A1 (en) 2010-03-25 2011-09-29 Quantalife, Inc. Droplet generation for droplet-based assays
US8951939B2 (en) 2011-07-12 2015-02-10 Bio-Rad Laboratories, Inc. Digital assays with multiplexed detection of two or more targets in the same optical channel
WO2011120006A1 (en) 2010-03-25 2011-09-29 Auantalife, Inc. A Delaware Corporation Detection system for droplet-based assays
US9492797B2 (en) 2008-09-23 2016-11-15 Bio-Rad Laboratories, Inc. System for detection of spaced droplets
US11130128B2 (en) 2008-09-23 2021-09-28 Bio-Rad Laboratories, Inc. Detection method for a target nucleic acid
US9417190B2 (en) 2008-09-23 2016-08-16 Bio-Rad Laboratories, Inc. Calibrations and controls for droplet-based assays
US9598725B2 (en) 2010-03-02 2017-03-21 Bio-Rad Laboratories, Inc. Emulsion chemistry for encapsulated droplets
US9764322B2 (en) 2008-09-23 2017-09-19 Bio-Rad Laboratories, Inc. System for generating droplets with pressure monitoring
US8633015B2 (en) 2008-09-23 2014-01-21 Bio-Rad Laboratories, Inc. Flow-based thermocycling system with thermoelectric cooler
US10512910B2 (en) 2008-09-23 2019-12-24 Bio-Rad Laboratories, Inc. Droplet-based analysis method
US12090480B2 (en) 2008-09-23 2024-09-17 Bio-Rad Laboratories, Inc. Partition-based method of analysis
CN102232117A (zh) * 2008-10-14 2011-11-02 卡里斯Mpi公司 描绘肿瘤类型生物标志模式和特征集的基因靶和基因表达的蛋白靶
EP3722810A3 (en) * 2009-02-11 2021-01-13 Caris MPI, Inc. Molecular profiling of tumors
GB2480980A (en) * 2009-03-02 2011-12-07 Trackfive Diagnostics Inc Methods for predicting cancer response to EGFR inhibitors
JP5992325B2 (ja) 2009-04-06 2016-09-14 ワイス・エルエルシー 乳癌のための、ネラチニブを活用する治療計画
HUE044629T2 (hu) 2009-07-06 2019-11-28 Boehringer Ingelheim Int Eljárás BIBW2992, annak sói, valamint e hatóanyagot tartalmazó szilárd gyógyászati készítmények szárítására
EP2473618B1 (en) 2009-09-02 2015-03-04 Bio-Rad Laboratories, Inc. System for mixing fluids by coalescence of multiple emulsions
US20130029339A1 (en) 2009-09-09 2013-01-31 The General Hospital Corporation Use of microvesicles in analyzing kras mutations
WO2011031982A1 (en) * 2009-09-10 2011-03-17 Myriad Genetics, Inc. Methods and compositions for predicting cancer therapy response
US7947653B1 (en) 2009-10-09 2011-05-24 Cold Spring Harbor Laboratory Methods for treating epidermal growth factor receptor tyrosine kinase inhibitor-resistant cancers
US8323883B1 (en) 2009-10-09 2012-12-04 Cold Spring Harbor Laboratory Methods of assessing therapeutic benefits of patients having cancers resistant to epidermal growth factor receptor kinase inhibitors
CN107441058A (zh) 2009-11-09 2017-12-08 惠氏有限责任公司 包衣药物球状体及消除或减少病症如呕吐和腹泻的用途
JP2013510564A (ja) 2009-11-13 2013-03-28 パンガエア ビオテック、ソシエダッド、リミターダ 肺癌におけるチロシンキナーゼ阻害剤に対する応答を予測するための分子バイオマーカー
WO2011063416A2 (en) 2009-11-23 2011-05-26 The General Hospital Corporation Microfluidic devices for the capture of biological sample components
US10731221B2 (en) 2009-12-11 2020-08-04 Dignity Health Diagnosing IDH1 related subgroups and treatment of cancer
WO2011072258A1 (en) * 2009-12-11 2011-06-16 Catholic Healthcare West Pi3k/akt pathway subgroups in cancer: methods of using biomarkers for diagnosis and therapy
US20110224205A1 (en) * 2010-02-11 2011-09-15 National Taiwan University Use of curcumin or its analogues in cancer therapy utilizing epidermal growth factor receptor tyrosine kinase inhibitor
NZ602084A (en) 2010-03-11 2014-07-25 Merrimack Pharmaceuticals Inc Use of erbb3 inhibitors in the treatment of triple negative and basal-like breast cancers
EP2548027A2 (en) * 2010-03-18 2013-01-23 Institut National de la Santé et de la Recherche Médicale Method for predicting the responsiveness to chemotherapy
CA2767114A1 (en) 2010-03-25 2011-09-29 Bio-Rad Laboratories, Inc. Droplet transport system for detection
CN102234683B (zh) * 2010-04-23 2013-07-17 广州益善生物技术有限公司 一种egfr基因突变检测液相芯片
CN101858909B (zh) * 2010-05-28 2013-07-03 广州瑞博奥生物科技有限公司 检测磷酸化表皮生长因子受体的试剂盒及其制备方法
NZ608313A (en) 2010-09-24 2013-12-20 Univ Leland Stanford Junior Direct capture, amplification and sequencing of target dna using immobilized primers
JP5996431B2 (ja) * 2010-09-30 2016-09-21 Ｌｓｉｐファンド運営合同会社 優性変異遺伝子発現抑制剤
JP5828901B2 (ja) 2010-10-29 2015-12-09 イミュノジェン， インコーポレイテッド 新規ｅｇｆｒ結合分子およびその免疫抱合体
WO2012058592A2 (en) 2010-10-29 2012-05-03 Immunogen, Inc. Non-antagonistic egfr-binding molecules and immunoconjugates thereof
CA3215088A1 (en) 2010-11-01 2012-05-10 Bio-Rad Laboratories, Inc. System for forming emulsions
WO2012065071A2 (en) * 2010-11-12 2012-05-18 The Broad Institute Of Mit And Harvard Methods of predicting response to egfr antibody therapy
WO2012065705A1 (en) 2010-11-19 2012-05-24 Roche Diagnostics Gmbh Novel complex mutation in the epidermal growth factor receptor kinase domain
US20120164641A1 (en) 2010-12-22 2012-06-28 Roche Molecular Systems, Inc. Methods and Compositions for Detecting Mutation in the Human Epidermal Growth Factor Receptor Gene
CN102140518B (zh) * 2011-01-18 2013-02-06 杭州迪安医学检验中心有限公司 肺癌相关表皮生长因子受体egfr外显子突变定量检测试剂盒及方法
US8914238B2 (en) 2011-01-28 2014-12-16 Biodesix, Inc. Method for predicting breast cancer patient response to endocrine therapy
WO2012103442A2 (en) 2011-01-28 2012-08-02 The Broad Institute, Inc. Paired end bead amplification and high throughput sequencing
US9556473B2 (en) 2011-02-15 2017-01-31 Leica Biosystems Newcastle Ltd Methods for identifying nucleic acid sequences
CN103649331A (zh) 2011-02-15 2014-03-19 莱卡生物系统纽卡斯尔有限责任公司 用于mrna的定位的原位检测的方法
US12097495B2 (en) 2011-02-18 2024-09-24 Bio-Rad Laboratories, Inc. Methods and compositions for detecting genetic material
EP2492688A1 (en) 2011-02-23 2012-08-29 Pangaea Biotech, S.A. Molecular biomarkers for predicting response to antitumor treatment in lung cancer
AU2012231098B2 (en) 2011-03-18 2016-09-29 Bio-Rad Laboratories, Inc. Multiplexed digital assays with combinatorial use of signals
WO2012129145A1 (en) 2011-03-18 2012-09-27 OSI Pharmaceuticals, LLC Nscle combination therapy
EP3395957B1 (en) 2011-04-25 2020-08-12 Bio-Rad Laboratories, Inc. Methods and compositions for nucleic acid analysis
JP5930825B2 (ja) * 2011-05-06 2016-06-08 アークレイ株式会社 Ｅｇｆｒエクソン１９多型検出試験用試薬キット及びその用途
EP2737089B1 (en) 2011-07-29 2017-09-06 Bio-rad Laboratories, Inc. Library characterization by digital assay
US10466160B2 (en) 2011-08-01 2019-11-05 Celsee Diagnostics, Inc. System and method for retrieving and analyzing particles
ES2797448T3 (es) 2011-08-01 2020-12-02 Bio Rad Laboratories Sistema de captura de células
US9404864B2 (en) 2013-03-13 2016-08-02 Denovo Sciences, Inc. System for imaging captured cells
US9174216B2 (en) 2013-03-13 2015-11-03 DeNovo Science, Inc. System for capturing and analyzing cells
US10364464B2 (en) 2011-08-08 2019-07-30 The Broad Institute, Inc. Compositions and methods for co-amplifying subsequences of a nucleic acid fragment sequence
US9738935B2 (en) 2011-11-10 2017-08-22 Roche Molecular Systems, Inc. Complex mutations in the epidermal growth factor receptor kinase domain
EP2794010A4 (en) 2011-11-21 2015-10-21 Immunogen Inc METHOD OF TREATING TUMORS RESISTANT TO EGFR THERAPIES BY A CYTOTOXIC EGFR-AGENT ANTIBODY CONJUGATE
US9260714B2 (en) 2011-12-02 2016-02-16 Roche Molecular Systems, Inc. Suppression of non-specific amplification with high-homology oligonucleotides
KR101963230B1 (ko) 2011-12-26 2019-03-29 삼성전자주식회사 복수개의 단일 항체를 포함하는 단백질 복합체
EP2653558B1 (en) 2012-04-18 2015-10-07 Roche Diagniostics GmbH A method of detecting nucleic acid targets using a statistical classifier
CN102732636B (zh) * 2012-07-17 2014-01-15 海南医学院 一种检测肿瘤细胞egfr基因突变的芯片
CN102851375B (zh) * 2012-09-11 2014-02-19 上海源奇生物医药科技有限公司 检测egfr基因突变的引物、探针及其试剂盒和使用方法
KR101911438B1 (ko) * 2012-10-31 2018-10-24 삼성전자주식회사 이중 특이 항원 결합 단백질 복합체 및 이중 특이 항체의 제조 방법
US20140341884A1 (en) * 2012-12-04 2014-11-20 Roche Molecular Systems, Inc. Novel Complex Mutations in the Epidermal Growth Factor Receptor Kinase Domain
US9752181B2 (en) 2013-01-26 2017-09-05 Denovo Sciences, Inc. System and method for capturing and analyzing cells
MY186126A (en) 2013-03-06 2021-06-24 Astrazeneca Ab Quinazoline inhibitors of activating mutant forms of epidermal growth factor receptor
US9873913B2 (en) 2013-03-08 2018-01-23 Roche Molecular Systems, Inc. Mutation testing
US20140287417A1 (en) 2013-03-08 2014-09-25 Roche Molecular Systems, Inc. EGFR Blood Monitoring
US9707562B2 (en) 2013-03-13 2017-07-18 Denovo Sciences, Inc. System for capturing and analyzing cells
US9856535B2 (en) 2013-05-31 2018-01-02 Denovo Sciences, Inc. System for isolating cells
US10391490B2 (en) 2013-05-31 2019-08-27 Celsee Diagnostics, Inc. System and method for isolating and analyzing cells
CN103333963A (zh) * 2013-06-09 2013-10-02 中国人民解放军第四军医大学 Egfr突变检测引物组及其用途
JP6463675B2 (ja) * 2013-06-19 2019-02-06 学校法人 久留米大学 上皮成長因子受容体チロシンキナーゼ阻害薬の治療効果を予測する方法
AU2014287209B2 (en) 2013-07-09 2019-01-24 Dana-Farber Cancer Institute, Inc. Kinase inhibitors for the treatment of disease
EP3087394A2 (en) 2013-12-27 2016-11-02 Merrimack Pharmaceuticals, Inc. Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies
US9242965B2 (en) 2013-12-31 2016-01-26 Boehringer Ingelheim International Gmbh Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors
CN103923975B (zh) * 2014-01-27 2016-01-20 上海涌泰生物医药科技有限公司 一种检测egfr基因外显子19缺失突变的试剂盒和方法
WO2015178946A1 (en) 2014-04-04 2015-11-26 Biodesix, Inc. Treatment selection for lung cancer patients using mass spectrum of blood-based sample
JP6905464B2 (ja) * 2014-07-28 2021-07-21 フンダシオ インスティトゥ マー ディンヴェスティガシオンズ メディクー（イーエメイーエメ） 上皮増殖因子受容体遺伝子の細胞外ドメインｉｉｉ内の変異
US9994914B2 (en) 2014-10-09 2018-06-12 Roche Molecular Systems, Inc. Mutation in the epidermal growth factor receptor kinase domain
KR101692044B1 (ko) * 2014-12-05 2017-01-04 사회복지법인 삼성생명공익재단 교모세포종에서 표피 성장인자 수용체 억제제의 치료 효과를 예측하는 방법
US20160333087A1 (en) * 2015-05-12 2016-11-17 Bioven 3 Limited Methods and compositions for inhibition of egf/egfr pathway in combination with tyrosine kinase inhibitors
US10184006B2 (en) 2015-06-04 2019-01-22 Merrimack Pharmaceuticals, Inc. Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors
MX2018009804A (es) * 2016-02-12 2018-11-09 Nantomics Llc Identificacion de gran alcance de neoepitopos especificos para pacientes como objetivos terapeuticos para inmunoterapias de cancer.
CN105624309B (zh) * 2016-02-23 2020-04-21 深圳华大生命科学研究院 检测EGFR和/或K-ras基因突变的引物、探针及试剂盒
CN105866217B (zh) * 2016-03-21 2018-04-10 杭州市红十字会医院 三尖杉酯碱癌症治疗效果检测装置及方法
KR102449693B1 (ko) * 2016-05-25 2022-09-30 주식회사 젠큐릭스 상피세포 성장인자 수용체 유전자 돌연변이 검출용 조성물 및 이를 포함하는 키트
CA3060443A1 (en) 2017-04-19 2018-10-25 Board Of Regents, The University Of Texas System Immune cells expressing engineered antigen receptors
CN109937603B (zh) * 2017-05-03 2021-12-28 华为技术有限公司 基于竞争的传输方法和设备
US10299039B2 (en) 2017-06-02 2019-05-21 Apple Inc. Audio adaptation to room
CN112980667B (zh) 2017-08-29 2024-09-17 伯乐实验室有限公司 用于分离和分析细胞的系统和方法
WO2019074920A1 (en) * 2017-10-10 2019-04-18 Oncocyte Corporation METHODS AND COMPOSITIONS FOR THE DETECTION AND DIAGNOSIS OF BREAST CANCER
CN109722476A (zh) * 2017-10-31 2019-05-07 北京雅康博生物科技有限公司 用于检测egfr基因2237-2257位突变的引物、探针及试剂盒
EP3788069A1 (en) * 2018-05-01 2021-03-10 The United States Of America As Represented By The Secretary, Department Of Health And Human Services T cell receptors which recognize mutated egfr
WO2020080871A2 (ko) * 2018-10-18 2020-04-23 (주)신테카바이오 암 약물 반응성 판단을 위한 바이오 마커 조성물, 바이오 마커 조성물을 이용한 암 약물 반응성 판단 방법 및 암 약물 반응성 판단을 위한 바이오 마커 조성물 검출용 진단칩
EP3931224A4 (en) 2019-02-26 2023-03-01 Janssen Biotech, Inc. COMBINATION THERAPIES AND PATIENT STRATIFICATION WITH BISPECIFIC ANTI-EGFR/C-MET ANTIBODIES
US10633693B1 (en) 2019-04-16 2020-04-28 Celsee Diagnostics, Inc. System and method for leakage control in a particle capture system
US11273439B2 (en) 2019-05-07 2022-03-15 Bio-Rad Laboratories, Inc. System and method for target material retrieval from microwells
CN114072490A (zh) 2019-05-07 2022-02-18 伯乐实验室有限公司 用于自动化的单细胞加工的系统和方法
US11879013B2 (en) 2019-05-14 2024-01-23 Janssen Biotech, Inc. Combination therapies with bispecific anti-EGFR/c-Met antibodies and third generation EGFR tyrosine kinase inhibitors
AU2020290981B2 (en) 2019-06-14 2024-03-07 Bio-Rad Laboratories, Inc. System and method for automated single cell processing and analyses
EP4365309A3 (en) 2019-11-06 2024-08-21 The Board of Trustees of the Leland Stanford Junior University Methods and systems for analyzing nucleic acid molecules
US11475981B2 (en) 2020-02-18 2022-10-18 Tempus Labs, Inc. Methods and systems for dynamic variant thresholding in a liquid biopsy assay
US11211147B2 (en) 2020-02-18 2021-12-28 Tempus Labs, Inc. Estimation of circulating tumor fraction using off-target reads of targeted-panel sequencing
US11211144B2 (en) 2020-02-18 2021-12-28 Tempus Labs, Inc. Methods and systems for refining copy number variation in a liquid biopsy assay
CN111154881A (zh) * 2020-03-09 2020-05-15 南京实践医学检验有限公司 一种急性髓系白血病中基因突变的检测试剂盒及应用
US11504719B2 (en) 2020-03-12 2022-11-22 Bio-Rad Laboratories, Inc. System and method for receiving and delivering a fluid for sample processing
US20220025453A1 (en) * 2020-07-23 2022-01-27 Michael Y Sha Xenonucleic acid-mediated multiplex qpcr clamping technology for lung cancer mutation detection
CN114107449B (zh) * 2020-08-31 2024-04-09 中山大学孙逸仙纪念医院 一种单细胞内原位qPCR方法
CN111996193B (zh) * 2020-09-11 2024-02-20 北京键凯科技股份有限公司 一种有效抑制表皮生长因子受体表达的siRNA序列
US11783912B2 (en) 2021-05-05 2023-10-10 The Board Of Trustees Of The Leland Stanford Junior University Methods and systems for analyzing nucleic acid molecules
CN113564255A (zh) * 2021-08-13 2021-10-29 河北医科大学第四医院 一种lncRNA NEAT1_1的应用
DE102021126650A1 (de) 2021-10-14 2023-04-20 Rheinische Friedrich-Wilhelms-Universität Bonn, Körperschaft des öffentlichen Rechts Verfahren zur bestimmung der ansprechwahrscheinlichkeit einer malignen erkrankung auf eine behandlung mit einem pharmazeutischen hemmwirkstoff
CN114113265B (zh) * 2021-12-14 2023-08-08 郑州轻工业大学 一种适配体传感器及其制备方法
WO2023190967A1 (ja) * 2022-03-31 2023-10-05 Ｃｈｏｒｄｉａ Ｔｈｅｒａｐｅｕｔｉｃｓ株式会社 イミダゾ［４，５－ｂ］ピリジン誘導体による固形癌治療のためのバイオマーカー

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US234A (en) 1837-06-14 Improvement in machines for breaking hemp and flax
US5811A (en) 1848-09-26 Improvement in hemp-brakes
US3625214A (en) 1970-05-18 1971-12-07 Alza Corp Drug-delivery device
GB1541435A (en) 1975-02-04 1979-02-28 Searle & Co Immunological materials
US4046784A (en) 1975-04-04 1977-09-06 Texaco Development Corporation Boride catalyst for epoxidizing olefinic compounds
US4348376A (en) 1980-03-03 1982-09-07 Goldenberg Milton David Tumor localization and therapy with labeled anti-CEA antibody
US4460561A (en) 1980-03-03 1984-07-17 Goldenberg M David Tumor localization and therapy with labeled antibodies specific to intracellular tumor-associated markers
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4444744A (en) 1980-03-03 1984-04-24 Goldenberg Milton David Tumor localization and therapy with labeled antibodies to cell surface antigens
US4361544A (en) 1980-03-03 1982-11-30 Goldenberg Milton David Tumor localization and therapy with labeled antibodies specific to intracellular tumor-associated markers
US4468457A (en) 1981-06-01 1984-08-28 David M. Goldenberg Method for producing a CSAp tryptic peptide and anti-CSAp antibodies
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US4818709A (en) 1983-01-21 1989-04-04 Primus Frederick J CEA-family antigens, Anti-CEA antibodies and CEA immunoassay
US4460459A (en) 1983-02-16 1984-07-17 Anschutz Mining Corporation Sequential flotation of sulfide ores
US4906474A (en) 1983-03-22 1990-03-06 Massachusetts Institute Of Technology Bioerodible polyanhydrides for controlled drug delivery
US4624846A (en) 1983-07-29 1986-11-25 Immunomedics, Inc. Method for enhancing target specificity of antibody localization and clearance of non-target diagnostic and therapeutic principles
US4736866B1 (en) 1984-06-22 1988-04-12 Transgenic non-human mammals
IL73883A (en) 1984-12-20 1990-12-23 Yeda Res & Dev Monoclonal antibodies against tnf-alpha,hybridomas producing them and method for the purification of tnf-alpha
US4789734A (en) 1985-08-06 1988-12-06 La Jolla Cancer Research Foundation Vitronectin specific cell receptor derived from mammalian mesenchymal tissue
CH671155A5 (da) 1986-08-18 1989-08-15 Clinical Technologies Ass
US4932412A (en) 1986-12-18 1990-06-12 Immunomedics, Inc. Intraoperative and endoscopic tumor detection and therapy
US5541297A (en) 1988-04-01 1996-07-30 Immunomedics, Inc. Therapeutic conjugates of toxins and drugs
US4925648A (en) 1988-07-29 1990-05-15 Immunomedics, Inc. Detection and treatment of infectious and inflammatory lesions
US5175383A (en) 1989-02-17 1992-12-29 President And Fellows Of Harvard College Animal model for benign prostatic disease
US5459039A (en) 1989-05-12 1995-10-17 Duke University Methods for mapping genetic mutations
US5332567A (en) 1989-08-24 1994-07-26 Immunomedics Detection and treatment of infections with immunoconjugates
DE69025946T2 (de) 1989-09-08 1996-10-17 Univ Duke Modifikationen der struktur des egf-rezeptor-gens in menschlichen glioma
KR0162259B1 (ko) 1989-12-05 1998-12-01 아미 펙터 감염성 병변 및 염증성 병변을 검출 및 치료하기 위한 키메라 항체
US5763177A (en) 1990-06-11 1998-06-09 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex
US5567588A (en) 1990-06-11 1996-10-22 University Research Corporation Systematic evolution of ligands by exponential enrichment: Solution SELEX
US5707796A (en) 1990-06-11 1998-01-13 Nexstar Pharmaceuticals, Inc. Method for selecting nucleic acids on the basis of structure
US5660985A (en) 1990-06-11 1997-08-26 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands containing modified nucleotides
US5580737A (en) 1990-06-11 1996-12-03 Nexstar Pharmaceuticals, Inc. High-affinity nucleic acid ligands that discriminate between theophylline and caffeine
US5410016A (en) 1990-10-15 1995-04-25 Board Of Regents, The University Of Texas System Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers
US5217889A (en) 1990-10-19 1993-06-08 Roninson Igor B Methods and applications for efficient genetic suppressor elements
ATE201234T1 (de) 1991-03-18 2001-06-15 Univ New York Für menschlichen tumornekrose-faktor spezifische monoklonale und chimäre antikörper
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
DE4129533A1 (de) 1991-09-05 1993-03-11 Max Planck Gesellschaft Mutierter wachstumsfaktorrezeptor als arzneimittel und seine verwendung zur behandlung von krebs
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
CA2163107C (en) 1993-05-17 2001-04-17 David Milton Goldenberg Improved detection and therapy of lesions with biotin/avidin-metal chelating protein conjugates
US5837832A (en) 1993-06-25 1998-11-17 Affymetrix, Inc. Arrays of nucleic acid probes on biological chips
US5593688A (en) 1993-06-25 1997-01-14 Nexstar Pharmaceuticals, Inc. Liposomal targeting of ischemic tissue
US5443953A (en) 1993-12-08 1995-08-22 Immunomedics, Inc. Preparation and use of immunoconjugates
EP0657811B1 (en) 1993-12-09 1998-09-02 STMicroelectronics S.r.l. Integrated circuitry for checking the utilization rate of redundancy memory elements in a semiconductor memory device
US5807522A (en) 1994-06-17 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods for fabricating microarrays of biological samples
US5686578A (en) 1994-08-05 1997-11-11 Immunomedics, Inc. Polyspecific immunoconjugates and antibody composites for targeting the multidrug resistant phenotype
CA2195557C (en) 1994-08-12 2006-10-17 Shui-On Leung Immunoconjugates and humanized antibodies specific for b-cell lymphoma and leukemia cells
US5556752A (en) 1994-10-24 1996-09-17 Affymetrix, Inc. Surface-bound, unimolecular, double-stranded DNA
US5599695A (en) 1995-02-27 1997-02-04 Affymetrix, Inc. Printing molecular library arrays using deprotection agents solely in the vapor phase
DE69522717T2 (de) 1995-03-30 2002-02-14 Pfizer Inc., New York Chinazolinderivate
AU5343096A (en) 1995-04-27 1996-11-18 Zeneca Limited Quinazoline derivatives
GB9508565D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quiazoline derivative
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5624711A (en) 1995-04-27 1997-04-29 Affymax Technologies, N.V. Derivatization of solid supports and methods for oligomer synthesis
US6699843B2 (en) 1995-06-07 2004-03-02 Gilead Sciences, Inc. Method for treatment of tumors using nucleic acid ligands to PDGF
AU7286696A (en) 1995-10-13 1997-05-07 F. Hoffmann-La Roche Ag Antisense oligomers
EP0892789B2 (en) 1996-04-12 2009-11-18 Warner-Lambert Company LLC Irreversible inhibitors of tyrosine kinases
US6015670A (en) 1996-05-17 2000-01-18 Hexagen Technology Limited Methods for identifying a mutation in a gene of interest without a phenotypic guide using ES cells
US5861251A (en) * 1996-10-15 1999-01-19 Bioneer Corporation Lyophilized reagent for polymerase chain reaction
US5814500A (en) 1996-10-31 1998-09-29 The Johns Hopkins University School Of Medicine Delivery construct for antisense nucleic acids and methods of use
UA73073C2 (uk) 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
US6011577A (en) 1997-06-30 2000-01-04 Polaroid Corporation Modular optical print head assembly
ZA986729B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitors of tyrosine kinases
ZA986732B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
TW436485B (en) 1997-08-01 2001-05-28 American Cyanamid Co Substituted quinazoline derivatives
CA2335649A1 (en) 1998-07-20 2000-01-27 Variagenics, Inc. Gene sequence variances with utility in determining the treatment of disease
US6821724B1 (en) * 1998-09-17 2004-11-23 Affymetrix, Inc. Methods of genetic analysis using nucleic acid arrays
AU2002218151A1 (en) 2000-11-24 2002-06-03 Pantheco A/S Pna analogues
CA2753372C (en) 2001-06-14 2018-08-07 The Regents Of The University Of California Mutations in the bcr-abl tyrosine kinase associated with resistance to sti-571
US20030198627A1 (en) 2001-09-01 2003-10-23 Gert-Jan Arts siRNA knockout assay method and constructs
US7250289B2 (en) * 2002-11-20 2007-07-31 Affymetrix, Inc. Methods of genetic analysis of mouse
WO2005006940A2 (en) * 2003-06-19 2005-01-27 University Of Medicine And Dentistry Of New Jersey Detection of mutations in nucleic acid sequences
WO2005018677A2 (en) 2003-08-01 2005-03-03 Wyeth Holdings Corporation Use of combination of an epidermal growth factor receptor kinase inhibitor and cytotoxic agents for treatment and inhibition of cancer
WO2005079434A2 (en) 2004-02-17 2005-09-01 The University Of North Carolina At Chapel Hill Modulation of epidermal growth factor heterodimer activity
AU2005228446B2 (en) * 2004-03-31 2007-02-22 Dana-Farber Cancer Institute, Inc. Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments
ES2564127T5 (es) 2004-06-04 2020-03-26 Genentech Inc Mutaciones en EGFR

Also Published As

Publication number Publication date
EP2423331A3 (en) 2012-06-27
JP2007531525A (ja) 2007-11-08
US20210017604A1 (en) 2021-01-21
EP2447375A2 (en) 2012-05-02
AU2007202288A1 (en) 2007-06-14
ES2741547T3 (es) 2020-02-11
JP6557646B2 (ja) 2019-08-07
WO2005094357A3 (en) 2008-12-24
WO2005094357A2 (en) 2005-10-13
AU2015201692A1 (en) 2015-04-23
CN102586431B (zh) 2015-04-22
EP3611273A1 (en) 2020-02-19
AU2005228446C1 (en) 2005-10-13
HK1254906A1 (zh) 2019-08-02
JP4468475B2 (ja) 2010-05-26
US20080234264A1 (en) 2008-09-25
KR20130008075A (ko) 2013-01-21
US8465916B2 (en) 2013-06-18
CN104774931B (zh) 2017-11-10
AU2015201692B2 (en) 2017-03-02
BRPI0508286B1 (pt) 2020-12-29
JP4350148B2 (ja) 2009-10-21
DK2447375T3 (da) 2019-07-29
US9035036B2 (en) 2015-05-19
US20130316935A1 (en) 2013-11-28
CN107988363A (zh) 2018-05-04
CN104774931A (zh) 2015-07-15
JP2010051316A (ja) 2010-03-11
JP5688399B2 (ja) 2015-03-25
AU2012202668B2 (en) 2015-02-05
ES2741573T3 (es) 2020-02-11
EP2423331A2 (en) 2012-02-29
US20180251860A1 (en) 2018-09-06
US20150176081A1 (en) 2015-06-25
US7964349B2 (en) 2011-06-21
ES2425749T3 (es) 2013-10-17
EP2423331B1 (en) 2019-05-08
SI1733056T1 (sl) 2013-10-30
US10000815B2 (en) 2018-06-19
DK2423331T3 (da) 2019-07-29
EP2439285B1 (en) 2019-05-08
DK2439285T3 (da) 2019-07-29
JP2015023865A (ja) 2015-02-05
EP2439285A1 (en) 2012-04-11
CA2556227C (en) 2013-03-19
JP5449943B2 (ja) 2014-03-19
US8105769B2 (en) 2012-01-31
US12006555B2 (en) 2024-06-11
EP2439284A1 (en) 2012-04-11
ES2741574T3 (es) 2020-02-11
EP2447375A3 (en) 2012-08-22
EP2439284B1 (en) 2019-05-08
AU2005228446A1 (en) 2005-10-13
AU2007202288B2 (en) 2012-02-09
JP2009171965A (ja) 2009-08-06
EP1733056A4 (en) 2009-08-12
BRPI0508286B8 (pt) 2021-05-25
AU2012202668A1 (en) 2012-05-31
AU2012202668B9 (en) 2015-02-12
CN104480200A (zh) 2015-04-01
CA2556227A1 (en) 2005-10-13
AU2005228446B2 (en) 2007-02-22
EP1733056A2 (en) 2006-12-20
CN102586431A (zh) 2012-07-18
JP2017074048A (ja) 2017-04-20
US20080207615A1 (en) 2008-08-28
KR20070031894A (ko) 2007-03-20
EP2447375B1 (en) 2019-05-08
KR20120087880A (ko) 2012-08-07
KR101368446B1 (ko) 2014-02-28
EP1733056B1 (en) 2013-05-22
US20080096212A1 (en) 2008-04-24
US7294468B2 (en) 2007-11-13
CN107794302B (zh) 2022-03-15
ES2741546T3 (es) 2020-02-11
HK1252399A1 (zh) 2019-05-24
JP2013059339A (ja) 2013-04-04
US20060147959A1 (en) 2006-07-06
DK1733056T3 (da) 2013-08-26
CN101501211A (zh) 2009-08-05
CN104480200B (zh) 2017-12-29
CN107794302A (zh) 2018-03-13
KR101347613B1 (ko) 2014-01-06
US10669589B2 (en) 2020-06-02
BRPI0508286A (pt) 2007-07-31
HK1212397A1 (en) 2016-06-10
HK1208250A1 (en) 2016-02-26
KR101289774B1 (ko) 2013-08-07
PT1733056E (pt) 2013-08-29

Similar Documents

Publication Publication Date Title
DK2423331T3 (da) Fremgangsmåde til at bestemme reaktivitet af cancer på behandlinger målrettet mod epidermal vækstfaktor-receptor
DK1948693T3 (da) Monoklonale antistoffer mod claudin-18 til behandling af cancer
DK2409728T3 (da) System til ultralydsbehandling af væv
DK2068874T3 (da) Fremgangsmåder til behandling af multiple myelom med anvendelse af kombinationsterapier baseret på anti-cs1 antistoffer
LTC1735348I2 (lt) Antikūnas prieš žmogaus epiderminio augimo faktoriaus receptorių
DK3401334T5 (da) Monoklonale antistoffer mod claudin-18 til cancerbehandling
DK1765391T3 (da) Bakterielle præparater til behandlingen af cancer
DK3403657T3 (da) Anvendelse af oligouronater til behandling af slimhyperviskositet
DK1781604T3 (da) Bis(thio-hydrazid-amid)-salte til behandling af cancere
DK1948180T3 (da) Kombinationsbehandling af cancer omfattende EGFR/HER2 inhibitorer
NL1029015A1 (nl) Therapeutische verbindingen.
DK1893649T3 (da) Fremgangsmåde til forstærkning af opioide analgetikas virkninger på smerte
DK1748077T3 (da) Fremgangsmåde til fremstilling af protein
DK1499730T3 (da) Immunokonjugater til behandling af tumorer
DE602005023972D1 (de) Vereinfachte wafer-ausrichtung
DK1727782T3 (da) Fremgangsmåde til fremstilling af aminophenolforbindelser
DE602005017683D1 (de) Winkelverstellvorrichtung
DK1814555T3 (da) S-mirtazapin til behandling af hedeture
DK3332789T3 (da) Cladribinkur til behandling af multipel sklerose
ATE424367T1 (de) Stelleinrichtung
NO20072717L (no) Sporingsanordning
FR2867058B1 (fr) Appareil de positionnement lingual
DK1788876T3 (da) Fremgangsmåde til fremstilling af imidazolforbindelser og salte og pseudopolymorfer deraf
SE0400530L (sv) Förfarande
DK2301576T3 (da) Terapeutisk anvendelse af anti-CS1-antistoffer